Loading…
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | $-284M | $-259M | $-214M | -49.1% | -78.0% | - |
| 2024 | $7M | $-192M | $-158M | $-160M | -21.1% | 2.0% | - |
| 2023 | $7M | $-139M | $-141M | $-109M | -33.0% | 192.0% | - |
| 2022 | $2M | $-104M | $-112M | $-106M | -34.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 2.36 | 6.88 | 7.02 | 1.54 |
| Operating Expense | 109.45 | 148.93 | 202.10 | 288.91 |
| Operating Income | -107.10 | -142.04 | -195.08 | -287.37 |
| EBITDA | -104.20 | -139.03 | -191.90 | -283.99 |
| EBIT | -107.10 | -142.04 | -195.08 | -287.37 |
| Pretax Income | -112.33 | -141.43 | -157.86 | -258.76 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -112.33 | -141.43 | -157.86 | -258.76 |
| Net Income Common Stockholders | -112.33 | -141.43 | -157.86 | -258.76 |
| Total Expenses | 109.45 | 148.93 | 202.10 | 288.91 |
| Research And Development | 82.26 | 118.01 | 163.55 | 245.07 |
| Selling General And Administration | 27.20 | 30.91 | 38.55 | 43.84 |
| Normalized EBITDA | -98.97 | -139.65 | -229.12 | -312.60 |
| Normalized Income | -107.10 | -142.04 | -195.08 | -287.37 |
| Basic EPS | -2.40 | -2.92 | -2.45 | 0 |
| Diluted EPS | -2.40 | -2.92 | -2.45 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -5.23 | 0.61 | 37.22 | 28.61 |
| Total Unusual Items Excluding Goodwill | -5.23 | 0.61 | 37.22 | 28.61 |
| Net Income From Continuing Operation Net Minority Interest | -112.33 | -141.43 | -157.86 | -258.76 |
| Reconciled Depreciation | 2.90 | 3.01 | 3.18 | 3.38 |
| Net Income From Continuing And Discontinued Operation | -112.33 | -141.43 | -157.86 | -258.76 |
| Total Operating Income As Reported | -115.23 | -154.54 | -195.08 | -287.37 |
| Diluted Average Shares | 46.89 | 48.45 | 64.39 | 0 |
| Basic Average Shares | 46.89 | 48.45 | 64.39 | 0 |
| Diluted NI Availto Com Stockholders | -112.33 | -141.43 | -157.86 | -258.76 |
| Net Income Including Noncontrolling Interests | -112.33 | -141.43 | -157.86 | -258.76 |
| Net Income Continuous Operations | -112.33 | -141.43 | -157.86 | -258.76 |
| Other Income Expense | -5.23 | 0.61 | 37.22 | 28.61 |
| Special Income Charges | -8.14 | -12.50 | 0 | 0 |
| Other Special Charges | 15 | 12.50 | 0 | 0 |
| Write Off | 0 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | -6.86 | 0 | 0 | 0 |
| Gain On Sale Of Security | 2.91 | 13.11 | 37.22 | 28.61 |
| General And Administrative Expense | 27.20 | 30.91 | 38.55 | 43.84 |
| Other Gand A | 27.20 | 30.91 | 38.55 | 43.84 |
| Operating Revenue | 2.36 | 6.88 | 7.02 | 1.54 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Celldex Therapeutics, Inc.this co. | CLDX | $2.5B | - | 4.06 | -49.1% | -5.72 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B | - | 7.52 | -19.3% | -32.50 |
| Immunome, Inc. | IMNM | $2.6B | - | 4.09 | -33.5% | -9.20 |
| Enliven Therapeutics, Inc. | ELVN | $2.6B | - | 5.48 | -22.6% | -17.36 |
| Vera Therapeutics, Inc. | VERA | $2.6B |
| - |
| 4.23 |
| -49.6% |
| -6.09 |
| Heartflow, Inc. | HTFL | $2.5B | - | 8.38 | -38.8% | -37.97 |
| Disc Medicine, Inc. | IRON | $2.5B | - | 3.38 | -28.7% | -7.48 |
| IDEAYA Biosciences, Inc. | IDYA | $2.5B | - | 2.41 | -11.1% | -11.82 |
| Guardian Pharmacy Services, Inc. | GRDN | $2.4B | 48.17 | 11.56 | 22.6% | 23.10 |
| Peer Median | - | 48.17 | 4.85 | -25.6% | -10.51 | |